Login / Signup

Clinical efficacy of infliximab level and anti-infliximab antibody measurement in patients with inflammatory bowel disease: An audit.

Mihika B DaveAlpa J DheraiDevendra C DesaiBhamini G KenyDhanashri N ShettySatish KulkarniKiran PeddyTester F Ashavaid
Published in: Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology (2020)
Most (80%) of the IBD patients had subtherapeutic IFX levels while high ATI titers were found in 27% of the patients. There was no correlation between infliximab dose and drug levels. Therapy modification based on drug level benefitted the majority. Our results suggest that measurement of IFX level assists in attaining therapeutic levels and improves clinical response.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • newly diagnosed
  • chronic kidney disease
  • prognostic factors
  • patients with inflammatory bowel disease
  • mesenchymal stem cells
  • bone marrow
  • replacement therapy